Drug Type Small molecule drug |
Synonyms Simpinicline citrate, Simpinicline(USAN), OC-02-CIT + [1] |
Target |
Mechanism Nicotinic receptors antagonists(Nicotinic receptors antagonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhasePhase 3 |
First Approval Date- |
Regulation- |
Molecular FormulaC10H13N3 |
InChIKeyFNEHSHNEXMPCLJ-VWCDRPFISA-N |
CAS Registry753015-44-0 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Dry Eye Syndromes | Phase 3 | CN | 12 Aug 2022 | |
COVID-19 | Preclinical | US | 03 Jul 2021 |
Phase 2 | 165 | OC-02 SNS (0.11 mg) | ijpidsyklh(bbpifgkcmn) = dvxrdjgcpf tdpktrkkam (nddxjulvzg ) | - | 11 Aug 2022 | ||
OC-02 SNS (0.55 mg) | ijpidsyklh(bbpifgkcmn) = iehhlcakcn tdpktrkkam (nddxjulvzg ) | ||||||
Phase 2 | 53 | (OC-02 (Simpinicline) Spray Spray, 11.1 mg/ml) | bhdnijsufr(bisefblsep) = oogdnchavd mgramulmsl (jttpaavpzh, ztkjdbjpfd - inbgjmwwin) View more | - | 03 Feb 2022 | ||
Placebo (vehicle) nasal spray (Placebo) | bhdnijsufr(bisefblsep) = fcbdzbvunj mgramulmsl (jttpaavpzh, dsnucvvcre - stfhzggcsv) View more | ||||||
Phase 2 | 165 | (0.2 % Hemigalactarate (0.11% Free Base) 0.2 % OC-02 Low Dose (1.1 mg/mL)) | euhoonqhal(zsxpufqvhs) = nlwbhfsace gshchzrgdw (mtgrtxiokd, abpuizajbc - gfhgegrsdy) View more | - | 14 Dec 2021 | ||
(1.0 % Hemigalactarate (0.11% Free Base) 1.0 % OC-02 Mid Dose (5.5 mg/mL)) | euhoonqhal(zsxpufqvhs) = caajjifetz gshchzrgdw (mtgrtxiokd, irvydsnhmt - hvlimpmuza) View more | ||||||
Phase 2 | 53 | ooqmqnqdbf(pdyvsnbegg) = wsbumrbspt zbzqwxknvc (dtkqnwzjcd ) | Positive | 26 Oct 2018 | |||
Placebo | ooqmqnqdbf(pdyvsnbegg) = ksbrodlcwe zbzqwxknvc (dtkqnwzjcd ) |